Hepatitis B Virus and Hepatitis C Virus Co-infection: An Evaluation of Eighty-Two Patients

Basit Öğe Kaydı
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorGunal, Ozgur
dc.contributor.authorYildiz, Orhan
dc.contributor.authorCelen, Mustafa Kemal
dc.contributor.authorAkhan, Sila
dc.contributor.authorBarut, Sener
dc.contributor.authorAyaz, Celal
dc.date.accessioned2024-04-24T17:24:32Z
dc.date.available2024-04-24T17:24:32Z
dc.date.issued2017
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: In this study, we aimed to investigate the characteristics and treatment results of 82 co-infected patients with hepatitis B virus (HBV)/hepatitis C virus (HCV). Materials and Methods: Four university hospitals evaluated HBV/HCV co-infection cases retrospectively. We analyzed the epidemiological, virological, clinical, and histopathological data and the results of treatment in patients co-infected with HBV and HCV. Pegylated interferon (peg IFN) plus ribavirin treatment was given to patients with HCV dominance. The results of patients receiving different treatment for HBV were evaluated. Results: The mean age of the patients was 44.3 +/- 14.7 years and 52.4% were female. The major risk factors were dental therapy, any surgical procedure, hemodialysis, and blood transfusion. The average HCV RNA level and HBV DNA level were found to be 1.36x10(6)+/- 3.06x10(6) IU/mL, and 1.55x10(7)+/- 4.83x10(7) IU/mL, respectively. On histopathology, the mean grade of necroinflammation was found to be 4.9 +/- 2.6 while the mean stage of fibrosis was 1.7 +/- 1.5 in 39 patients. 8.5% of patients were positive for both HCV-RNA and HBV-DNA positive and in 85.7% of cases, HCV infection was found to be dominant. The rate of sustained virologic response was 70.8% in 24 patients receiving peg IFN plus ribavirin therapy. Reactivation of HBV was found in 33.3% of cases. HBV DNA was negative in all patients who received oral antiviral therapy. Conclusion: In cases where both HCV RNA and HBV DNA were positive, HCV was predominant. This is especially noticeable in hemodialysis patientsen_US
dc.identifier.doi10.4274/vhd.75768
dc.identifier.endpage19en_US
dc.identifier.issn1307-9441
dc.identifier.issn2147-2939
dc.identifier.issue1en_US
dc.identifier.startpage14en_US
dc.identifier.urihttps://doi.org/10.4274/vhd.75768
dc.identifier.urihttps://hdl.handle.net/11468/19727
dc.identifier.volume23en_US
dc.identifier.wosWOS:000404629300005
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofViral Hepatit Dergisi-Viral Hepatitis Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis B Virusen_US
dc.subjectHepatitis C Virusen_US
dc.subjectCo-Infectionen_US
dc.subjectEpidemiologyen_US
dc.subjectTreatmenten_US
dc.titleHepatitis B Virus and Hepatitis C Virus Co-infection: An Evaluation of Eighty-Two Patientsen_US
dc.titleHepatitis B Virus and Hepatitis C Virus Co-infection: An Evaluation of Eighty-Two Patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu